Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis ; volume:58 ; number:4 ; day:17 ; month:4 ; year:2024 ; pages:600-609 ; date:7.2024
Therapeutic innovation & regulatory science ; 58, Heft 4 (17.4.2024), 600-609, 7.2024
- Urheber
-
Signorovitch, James
Zhang, Jialu
Brown, David
Dunnmon, Preston
Xiu, Liang
Done, Nicolae
Hsu, Kristen
Barbachano, Yolanda
Lousada, Isabelle
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-024-00641-6
- URN
-
urn:nbn:de:101:1-2408182126485.506439794893
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Signorovitch, James
- Zhang, Jialu
- Brown, David
- Dunnmon, Preston
- Xiu, Liang
- Done, Nicolae
- Hsu, Kristen
- Barbachano, Yolanda
- Lousada, Isabelle
- SpringerLink (Online service)
Ähnliche Objekte (12)
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
![Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks
Structural analysis of ex vivo amyloid fibrils from AL amyloidosis
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks
Structural analysis of ex vivo amyloid fibrils from AL amyloidosis
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks